Wedelolactone, A Medicinal Plant-Derived Coumestan, Induces Caspase-Dependent Apoptosis In Prostate Cancer Cells Via Downregulation Of PKCε Without Inhibiting Akt
October 2012
in “
International Journal of Oncology
”
Studysummary In this in vitro study, wedelolactone induced selective apoptosis in prostate cancer cells by inhibiting 5-Lox activity, suggesting it may have potential as a treatment for prostate cancer.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Wedelolactone (WDL), a compound from medicinal plants, was found to induce caspase-dependent apoptosis in prostate cancer cells by downregulating protein kinase Cε (PKCε) without affecting Akt. The study showed that WDL reduced the viability of both androgen-sensitive and androgen-independent prostate cancer cells in a dose-dependent manner, while sparing normal prostate epithelial cells. The apoptosis was linked to the inhibition of 5-lipoxygenase (5-Lox) activity, as it was prevented by 5-oxoETE, a 5-Lox metabolite. These findings suggested that WDL could be a promising therapeutic agent for prostate cancer treatment due to its selective action on cancer cells and novel mechanism of inducing apoptosis.
